BioRestorative Therapies (BRTX) 10-Q 23 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 19, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		3,133,329

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 12,793	$ 91,798
Inventories	2,492	1,945
Prepaid expenses and other current assets	28,546	20,570
Deferred offering costs	341,167	0
Total Current Assets	384,998	114,313
Property and equipment, net	662,502	493,856
Intangible assets, net	1,057,465	1,037,732
Security deposit	45,900	45,900
Total Assets	2,150,865	1,691,801
Current Liabilities:
Accounts payable	2,110,257	1,111,879
Accrued expenses and other current liabilities	1,969,286	1,466,506
Accrued interest	40,151	94,026
Current portion of notes payable, net of debt discount of $66,501 and $113,257 at September 30, 2015 and December 31, 2014, respectively	1,244,202	5,688,239
Deferred revenues	101,527	164,349
Total Current Liabilities	5,465,423	8,524,999
Accrued interest, non-current portion	39,420	5,195
Notes payable, non-current portion, net of debt discount of $6,654 and $0 at September 30, 2015 and December 31, 2014, respectively	422,182	50,000
Total Liabilities	$ 5,927,025	$ 8,580,194
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at September 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 2,882,200 and 1,725,596 shares at September 30, 2015 and December 31, 2014, respectively; Outstanding 2,854,268 and 1,697,664 shares at September 30, 2015 and December 31, 2014, respectively	2,882	1,726
Additional paid-in capital	26,457,238	18,541,907
Accumulated deficit	(30,204,280)	(25,400,026)
Treasury stock, at cost, 27,932 shares at September 30, 2015 and December 31, 2014	(32,000)	(32,000)
Total Stockholders' Deficiency	(3,776,160)	(6,888,393)
Total Liabilities and Stockholders' Deficiency	$ 2,150,865	$ 1,691,801

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current portion of notes payable, debt discount (in dollars)	$ 66,501	$ 113,257
Non-current portion of notes payable, debt discount (in dollars)	$ 7,818	$ 0
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, Authorized	30,000,000	30,000,000
Common stock, Issued	2,882,200	1,725,596
Common stock, Outstanding	2,854,268	1,697,664
Treasury stock, at cost, shares	27,932	27,932

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 96,122	$ 159,930	$ 429,788	$ 336,246
Cost of sales	50,921	66,115	201,998	108,541
Gross Profit	45,201	93,815	227,790	227,705
Operating Expenses
Marketing and promotion	40,412	41,840	134,440	89,169
Consulting	282,536	154,492	786,596	979,255
Research and development	615,648	290,707	1,474,992	1,077,778
General and administrative	596,515	502,783	2,210,442	1,687,415
Total Operating Expenses	1,535,111	989,822	4,606,470	3,833,617
Loss From Operations	(1,489,910)	(896,007)	(4,378,680)	(3,605,912)
Other (Expense) Income
Interest expense	(80,647)	(74,780)	(205,383)	(220,301)
Amortization of debt discount	(37,063)	(137,167)	(177,947)	(381,602)
Loss on extinguishment of notes payable, net	0	0	(26,029)	(49,094)
Warrant modification expense	(16,215)	0	(16,215)	(30,128)
Gain on settlement of payables	0	7,500	0	183,768
Total Other Expense	(133,925)	(204,447)	(425,574)	(497,357)
Net Loss	$ (1,623,835)	$ (1,100,454)	$ (4,804,254)	$ (4,103,269)
Net Loss Per Share
- Basic and Diluted (in dollars per share)	$ (0.57)	$ (0.81)	$ (2.11)	$ (3.51)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted (in shares)	2,829,416	1,352,188	2,275,223	1,170,139

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) - 9 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Treasury Stock
Beginning Balance at Dec. 31, 2014	$ (6,888,393)	$ 1,726	$ 18,541,907	$ (25,400,026)	$ (32,000)
Beginning Balance (in shares) at Dec. 31, 2014		1,725,596			(27,932)
Shares and warrants issued for cash	1,361,000	$ 228	1,360,772	0	$ 0
Shares and warrants issued for cash (in shares)		227,550			0
Conversion of notes payable and accrued interest into common stock	201,801	$ 41	201,760	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		41,359			0
Shares issued in satisfaction of accrued services	8,481	$ 1	8,480	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		943			0
Shares and warrants issued in connection with settlement agreement	152,000	$ 4	151,996	0	$ 0
Shares and warrants issued in connection with settlement agreement (in shares)		4,230			0
Warrants issued as debt discount in connection with notes payable	82,042	$ 0	82,042	0	$ 0
Shares and warrants issued in exchange of notes payable	5,142,065	$ 853	5,141,212	0	$ 0
Shares and warrants issued in exchange of notes payable (in shares)		853,360			0
Warrant modifications	22,115	$ 0	22,115	0	$ 0
Beneficial conversion features related to convertible notes payable	10,690	0	10,690	0	0
Stock-based compensation: - common stock	141,647	$ 28	141,619	0	$ 0
Stock-based compensation: - common stock (in shares)		27,698			0
Stock-based compensation: - options	794,646	$ 0	794,646	0	$ 0
Impact of share rounding as a result of reverse stock split	0	$ 1	(1)
Impact of share rounding as a result of reverse stock split (in shares)		1,464
Net loss	(4,804,254)	$ 0	0	(4,804,254)	0
Ending Balance at Sep. 30, 2015	$ (3,776,160)	$ 2,882	$ 26,457,238	$ (30,204,280)	$ (32,000)
Ending Balance (in shares) at Sep. 30, 2015		2,882,200			(27,932)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (4,804,254)	$ (4,103,269)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	177,947	381,602
Accretion of interest expense	47,626	0
Depreciation and amortization	150,646	73,889
Loss on sale of property and equipment	0	1,009
Stock-based compensation	936,293	1,075,499
Loss on extinguishment of note payables, net	26,029	49,094
Gain on settlement of payables	0	(183,768)
Warrant modification expense	16,215	30,128
Changes in operating assets and liabilities:
Inventories	(547)	580
Prepaid expenses and other current assets	(7,976)	11,629
Security deposit	0	(45,900)
Accounts payable	629,944	(488,416)
Accrued interest	(19,650)	3,919
Accrued interest, expenses and other current liabilities	842,545	445,749
Deferred revenues	(62,822)	154,662
Total Adjustments	2,736,250	1,509,676
Net Cash Used In Operating Activities	(2,068,004)	(2,593,593)
Cash Flows From Investing Activities
Purchases of property and equipment	(360,466)	(1,526)
Proceeds from sale of property and equipment	0	980
License maintenance costs	(75,000)	0
Net Cash Used In Investing Activities	(435,466)	(546)
Cash Flows From Financing Activities
Deferred offering costs	(8,050)	0
Proceeds from notes payable	950,015	670,000
Repayments of notes payable	0	(53,000)
Advances from director, officer and family member of officer	401,575	35,539
Repayment of advances from director and officer	(280,075)	(60,529)
Proceeds from exercise of warrants	0	80,000
Sales of common stock and warrants for cash	1,361,000	2,095,001
Net Cash Provided By Financing Activities	2,424,465	2,767,011
Net (Decrease) Increase In Cash	(79,005)	172,872
Cash - Beginning	91,798	201,098
Cash - Ending	12,793	373,970
Cash paid during the period for:
Interest	59,603	76,060
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	201,801	327,946
Accrued interest reclassified as principal in connection with note payable reissuance	0	73,058
Beneficial conversion features set up as debt discount	10,690	86,563
Accrued deferred offering costs	333,117	0
Accrued liabilities associated with purchases of property and equipment	96,441	0
Advances converted into note payable	65,000
Indebtedness satisfied via legal settlement	5,000	0
Warrant modification in connection with extension or exchanges of notes payable
Non-cash investing and financing activities:
Stock Issued	5,900	0
Shares and warrants issued in connection with issuance or extension of notes payable
Non-cash investing and financing activities:
Stock Issued	82,042	136,000
Shares and warrants issued in exchange for notes payable and accrued interest
Non-cash investing and financing activities:
Stock Issued	5,116,036	343,026
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Stock Issued	8,481	75,000
Shares and warrants issued in connection with settlement agreement
Non-cash investing and financing activities:
Stock Issued	$ 152,000	$ 71,050

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation BioRestorative Therapies, Inc. (together with its subsidiaries, “BRT” or the “Company”) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com D I S C www.stempearls.com The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 31, 2015. Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 30,000,000

Going Concern and Management Pl

Going Concern and Management Plans	9 Months Ended
	Sep. 30, 2015
Development Stage Enterprise [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management Plans As of September 30, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $ 5,080,425 3,776,160 1,623,835 4,804,254 The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to September 30, 2015, the Company has raised an aggregate of $ 637,500 150,000 405,000 65,002 646,703

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and nine months ended September 30, 2015. See Revenue Recognition – Research and Development Agreements below. Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the three and nine months ended September 30, 2015, the Company recognized revenue of $ 0 100,000 250,000 During the nine months ended September 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received payments in the aggregate amount of $ 260,766 688,891 587,364 101,527 During the three and nine months ended September 30, 2015, the Company recognized revenue related to research and development agreements of $ 96,122 423,588 159,376 334,401 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and nine months ended September 30, 2015, the Company recognized $ 0 6,000 During the three and nine months ended September 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 0 200 554 1,845 Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. September 30, 2015 2014 Options 810,200 439,200 Warrants 792,334 370,426 Convertible notes 170,561 21,221 Total potentially dilutive shares 1,773,095 830,847 The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities September 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,171 $ 4,739 Accrued payroll 978,255 679,277 Advances from related parties 56,500 - Accrued purchases of property and equipment - 174,801 Accrued research and development expenses 466,175 292,395 Accrued general and administrative expenses 421,432 315,294 Deferred rent 43,753 - Total $ 1,969,286 $ 1,466,506 During the nine months ended September 30, 2015, the Company received an aggregate of $ 401,575 280,075 65,000 75,000 October 30, 2015

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 625,000 478,018 - 1,103,018 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (188,333) - - (188,333) Recognition of debt discount - - - (186,635) [1] (186,635) Accretion of interest expense - - - 47,626 [1] 47,626 Amortization of debt discount - - - 177,947 177,947 Outstanding, September 30, 2015 $ - $ 595,000 [2] $ 1,145,703 $ (74,319) $ 1,666,384 [1] During the nine months ended September 30, 2015, notes in the aggregate amount of $ 538,018 450,015 88,003 [2] As of September 30, 2015, convertible notes with an aggregate principal balance of $ 595,000 190,000 Bermuda Lender On May 11, 2015, Cayman and a lender to Cayman (the “Bermuda Lender”) agreed to extend the maturity date of a note with a principal balance of $ 410,938 316,297 On May 27, 2015, the Company and the Bermuda Lender agreed to exchange five notes (including the note referred to in the above paragraph) with an aggregate principal amount of $ 4,410,937 69,436 746,730 186,682 15.00 672,056 40,000 December 31, 2015 31 5,327 Convertible Notes and Other Notes Issuances During the nine months ended September 30, 2015, the Company issued convertible notes with an aggregate principal balance of $ 625,000 615,000 1 12 10,000 25,885 10.00 82,042 During the nine months ended September 30, 2015, the Company issued notes payable with an aggregate principal amount of $ 478,018 400,015 including the issuance of a note payable in the principal amount of $ 75,000 a short term advance from a related party in the amount 65,000 mature between October 2015 and December 2015 78,003 Conversions, Exchanges and Other During the nine months ended September 30, 2015, pursuant to the original conversion terms of the convertible notes, the Company elected to convert convertible notes with an aggregate principal balance of $ 188,333 13,468 41,359 4.44 5.16 During the nine months ended September 30, 2015, the Company exchanged a convertible note in the principal amount of $ 16,667 827 3,600 504 During the nine months ended September 30, 2015, the Company elected to exchange notes payable with an aggregate principal balance of $ 592,874 25,296 103,030 25,756 15.00 92,725 15,249 20,197 During the nine months ended September 30, 2015, the contingently adjustable conversion ratio associated with a certain convertible note was resolved. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three and nine months ended September 30, 2015, the Company recognized $ 0 10,690 During the three and nine months ended September 30, 2014, the Company recognized $ 45,179 86,563

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Operating Lease During the three and nine months ended September 30, 2015, the Company recognized approximately $ 33,000 97,000 3,000 17,000 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. 4,230 30,000 7.60 12.00 152,000 The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and a discretionary bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments of $ 150,000 25,000 9.20 200,400 On March 9, 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. Pursuant to the employment agreement, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason” (each as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to his then annual base salary and certain benefits, plus $ 100,000 300,000 On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount currently $ 125,000 Consulting Agreements On August 13, 2015, a February 17, 2011 agreement for business advisory services that had expired on June 30, 2015 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of July 1, 2015 and provided for an expiration date of June 30, 2016 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $ 15,000 10,000 12.00 10,000 10.00 74,923

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Authorized Capital On December 19, 2014, the Company’s stockholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware effective January 1, 2015, and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 200,000,000 1,000,000 5,000,000 On September 4, 2015, the Compensation Committee of the Board increased the number of shares authorized to be issued pursuant to the Plan from 1,000,000 2,000,000 Private Common Stock and Warrant Offerings During the nine months ended September 30, 2015, the Company issued an aggregate of 227,550 91,589 8.00 15.00 322,732 24,500 11.60 18.80 10.00 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at annual rates ranging from 0 5 Stock Warrants For The Three Months Ended For The Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Risk free interest rate 1.50% - 1.69 % 1.64% - 1.76 % 1.32% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 5.00 5.00 1.96 - 5.00 Expected volatility 120 % 116 % 120% - 122 % 116% - 129 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and nine months ended September 30, 2015 was $ 4.21 3.63 3.00 3.40 On May 29, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 5,000 December 31, 2017 6,215 16,215 The Company recorded stock–based compensation expense of $ 74,923 1,500 168,626 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 379,912 13.25 Exercised - - Forfeited - - Outstanding, September 30, 2015 792,334 $ 15.71 3.7 $ - Exercisable, September 30, 2015 757,334 $ 15.05 3.7 $ - Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants 6.00 - 10.00 178,788 4.4 178,788 10.01 - 14.99 36,500 3.6 36,500 15.00 - 19.99 458,388 3.7 458,388 20.00 - 80.00 83,658 2.5 83,658 Variable [1] 35,000 - - 792,334 3.7 757,334 [1] Warrants to purchase 35,000 30.00 Stock Options For the Three Months Ended For the Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Risk free interest rate 1.58% - 2.19 % 1.82 % 1.33% - 2.19 % 1.50% - 2.54 % Expected term (years) 5.42 - 10.00 5.00 5.00 - 10.00 5.00 - 10.00 Expected volatility 120 % 116 % 120% - 122 % 116% - 121 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the options granted during the three and nine months ended September 30, 2015 was $ 7.52 7.60 5.40 4.80 See Note 6 – Commitments and Contingencies – Employment Agreements for details associated with the grant of stock options in connection with employment agreements. On January 23, 2015, the Company granted five-year options to consultants to purchase an aggregate of 5,000 9.40 3,750 625 625 39,200 On April 6, 2015, the Company elected a new director to replace a director who had previously resigned. Concurrent with the election, the Company granted a ten-year option to purchase 15,000 8.00 104,100 On August 13, 2015, the Company granted ten-year options to employees and advisors to purchase an aggregate of 21,000 8.75 13,500 7,500 157,900 On September 4, 2015, the Company issued ten-year options to employees, directors, advisors and consultants to purchase an aggregate of 505,250 7.00 201,750 303,500 1,000,000 2,250,000 The following table presents information related to stock-based compensation expense associated with stock options: Weighted Average Remaining For the Three Months Ended For The Nine Months Ended Unrecognized at Amortization September 30, September 30, September 30, Period 2015 2014 2015 2014 2015 (Years) Consulting $ 60,383 $ 35,662 $ 178,613 $ 287,237 $ 415,863 2.0 Research and development 115,625 80,275 348,777 233,989 666,047 [1] 2.3 General and administrative 59,189 21,280 192,333 126,259 679,893 2.0 $ 235,197 $ 137,217 $ 719,723 $ 647,485 $ 1,761,803 2.1 [1] Includes $ 252,937 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 66,000 8.80 Exercised - - Forfeited (35,000) 6.34 Outstanding, September 30, 2015 810,200 $ 12.16 7.8 $ - Exercisable, September 30, 2015 476,160 $ 14.94 7.3 $ - The above table excludes the impact of options to purchase an aggregate of 505,250 shares of common stock at an exercise price of $7.00 per share which are subject to stockholder approval of an increase in the number of shares authorized to be issued pursuant to the Plan from 1,000,000 to 2,250,000. As of September 30, 2015, stockholder approval had not been obtained. The annual meeting of stockholders is scheduled for December 22, 2015. The following table presents information related to stock options at September 30, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options 5.70 - 6.99 353,750 8.5 129,583 7.00 - 9.99 69,000 4.0 7,375 10.00 - 19.99 202,000 7.6 160,752 20.00 - 30.00 185,450 6.3 178,450 810,200 7.3 476,160 The above table excludes the impact of options to purchase an aggregate of 505,250 shares of common stock at an exercise price of $7.00 per share which are subject to stockholder approval of an increase in the number of shares authorized to be issued pursuant to the Plan from 1,000,000 to 2,250,000. As of September 30, 2015, stockholder approval had not been obtained. The annual meeting of stockholders is scheduled for December 22, 2015. Compensatory Common Stock Issuances During the nine months ended September 30, 2015, the Company issued an aggregate of 27,698 141,647 During the nine months ended September 30, 2015, the Company issued 943 8,481 For the Three Months Ended For The Nine Months Ended Unrecognized at September 30, September 30, September 30, 2015 2014 2015 2014 2015 Consulting $ 42,500 $ 88,200 $ 132,800 $ 322,700 $ - Research and development - 5,790 8,847 11,688 - $ 42,500 $ 93,990 $ 141,647 $ 334,388 $ -

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Short Term Advances Subsequent to September 30, 2015, the Company received an aggregate of $ 75,000 31,500 Private Common Stock and Warrant Offerings Subsequent to September 30, 2015, the Company issued an aggregate of 159,375 159,375 5.00 6.00 637,500 125,000 125,000 5.00 500,000 Notes Payable On October 9, 2015, the Company issued a two-month note payable to an affiliate of the Bermuda Lender with a principal amount of $ 150,000 10 Effective October 14, 2015, the Company and certain lenders agreed to exchange notes with an aggregate principal amount of $ 380,000 63,776 110,944 110,944 On November 9, 2015, pursuant to the provisions of a convertible note with a principal balance of $ 100,000 25,000 1,226 8,742 3.00 As of September 30, 2015 the Company reclassified principal amount of $ 430,000 39,420 License Agreement Subsequent to September 30, 2015, the Company, as licensee, and a stem cell treatment company, as licensor, entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company has granted to the licensor a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in United States locations certain intellectual property related to stem cell disc procedures that the licensor has licensed to the Company. In consideration of the sublicense, the licensor has agreed to pay the Company royalties on a per disc procedure basis.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and nine months ended September 30, 2015. See Revenue Recognition – Research and Development Agreements below.
Revenue Recognition	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the three and nine months ended September 30, 2015, the Company recognized revenue of $ 0 100,000 250,000 During the nine months ended September 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received payments in the aggregate amount of $ 260,766 688,891 587,364 101,527 During the three and nine months ended September 30, 2015, the Company recognized revenue related to research and development agreements of $ 96,122 423,588 159,376 334,401 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and nine months ended September 30, 2015, the Company recognized $ 0 6,000 During the three and nine months ended September 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 0 200 554 1,845
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. September 30, 2015 2014 Options 810,200 439,200 Warrants 792,334 370,426 Convertible notes 170,561 21,221 Total potentially dilutive shares 1,773,095 830,847
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory,” (“ASU 2015-11”). ASU 2015-11 amends the existing guidance to require that inventory should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using last-in, first-out or the retail inventory method. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently evaluating the effects of ASU 2015–11 on its condensed consolidated financial statements.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2015 2014 Options 810,200 439,200 Warrants 792,334 370,426 Convertible notes 170,561 21,221 Total potentially dilutive shares 1,773,095 830,847

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: September 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,171 $ 4,739 Accrued payroll 978,255 679,277 Advances from related parties 56,500 - Accrued purchases of property and equipment - 174,801 Accrued research and development expenses 466,175 292,395 Accrued general and administrative expenses 421,432 315,294 Deferred rent 43,753 - Total $ 1,969,286 $ 1,466,506

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Payable [Abstract]
Notes Payable	A summary of the notes payable activity during the nine months ended September 30, 2015 is presented below: Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 625,000 478,018 - 1,103,018 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (188,333) - - (188,333) Recognition of debt discount - - - (186,635) [1] (186,635) Accretion of interest expense - - - 47,626 [1] 47,626 Amortization of debt discount - - - 177,947 177,947 Outstanding, September 30, 2015 $ - $ 595,000 [2] $ 1,145,703 $ (74,319) $ 1,666,384 [1] During the nine months ended September 30, 2015, notes in the aggregate amount of $ 538,018 450,015 88,003 [2] As of September 30, 2015, convertible notes with an aggregate principal balance of $ 595,000 190,000

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions: For The Three Months Ended For The Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Risk free interest rate 1.50% - 1.69 % 1.64% - 1.76 % 1.32% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 5.00 5.00 1.96 - 5.00 Expected volatility 120 % 116 % 120% - 122 % 116% - 129 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Summary of Warrant Activity	A summary of the stock warrant activity during the nine months ended September 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 379,912 13.25 Exercised - - Forfeited - - Outstanding, September 30, 2015 792,334 $ 15.71 3.7 $ - Exercisable, September 30, 2015 757,334 $ 15.05 3.7 $ -
Information Related to Stock Warrants	The following table presents information related to stock warrants at September 30, 2015: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants 6.00 - 10.00 178,788 4.4 178,788 10.01 - 14.99 36,500 3.6 36,500 15.00 - 19.99 458,388 3.7 458,388 20.00 - 80.00 83,658 2.5 83,658 Variable [1] 35,000 - - 792,334 3.7 757,334 [1] Warrants to purchase 35,000 30.00
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Risk free interest rate 1.58% - 2.19 % 1.82 % 1.33% - 2.19 % 1.50% - 2.54 % Expected term (years) 5.42 - 10.00 5.00 5.00 - 10.00 5.00 - 10.00 Expected volatility 120 % 116 % 120% - 122 % 116% - 121 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Stock option expense	The following table presents information related to stock-based compensation expense associated with stock options: Weighted Average Remaining For the Three Months Ended For The Nine Months Ended Unrecognized at Amortization September 30, September 30, September 30, Period 2015 2014 2015 2014 2015 (Years) Consulting $ 60,383 $ 35,662 $ 178,613 $ 287,237 $ 415,863 2.0 Research and development 115,625 80,275 348,777 233,989 666,047 [1] 2.3 General and administrative 59,189 21,280 192,333 126,259 679,893 2.0 $ 235,197 $ 137,217 $ 719,723 $ 647,485 $ 1,761,803 2.1 [1] Includes $ 252,937
Summary of Option Activity	A summary of the stock option activity during the nine months ended September 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 66,000 8.80 Exercised - - Forfeited (35,000) 6.34 Outstanding, September 30, 2015 810,200 $ 12.16 7.8 $ - Exercisable, September 30, 2015 476,160 $ 14.94 7.3 $ -
Information Related to Stock Options	The following table presents information related to stock options at September 30, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options 5.70 - 6.99 353,750 8.5 129,583 7.00 - 9.99 69,000 4.0 7,375 10.00 - 19.99 202,000 7.6 160,752 20.00 - 30.00 185,450 6.3 178,450 810,200 7.3 476,160
Common Stock Award Expense	The following table presents information related to compensatory common stock expense: For the Three Months Ended For The Nine Months Ended Unrecognized at September 30, September 30, September 30, 2015 2014 2015 2014 2015 Consulting $ 42,500 $ 88,200 $ 132,800 $ 322,700 $ - Research and development - 5,790 8,847 11,688 - $ 42,500 $ 93,990 $ 141,647 $ 334,388 $ -

Business Organization, Nature20

Business Organization, Nature of Operations and Basis of Presentation - Additional Information (Detail)	Jul. 07, 2015shares
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company, the Company implemented a 1-for-20 reverse split
Changes in capital structure retroactive impact shares	200,000,000
Common stock, authorized	30,000,000

Going Concern and Management 21

Going Concern and Management Plans - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency		$ 5,080,425		$ 5,080,425
Stockholders deficiency		(3,776,160)		(3,776,160)		$ (6,888,393)
Net loss		$ (1,623,835)	$ (1,100,454)	(4,804,254)	$ (4,103,269)
Note principal and accrued interest converted to equity				$ (5,020,478)
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through equity financing	$ 637,500
Notes payable aggregate principal past due	646,703
Proceeds From Debt Financing	150,000
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	65,002
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$ 405,000

Calculation of Weighted Average

Calculation of Weighted Average Dilutive Common Shares (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,773,095	830,847
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	810,200	439,200
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	792,334	370,426
Convertible instruments
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	170,561	21,221

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	$ 101,527		$ 101,527		$ 164,349
Revenues	96,122	$ 159,930	429,788	$ 336,246
Deferred Revenue, Revenue Recognized			587,364
Revenue Received			688,891
Sublicense Agreement
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized	0		6,000
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues	96,122	159,376	423,588	334,401
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenues	0	$ 554	200	$ 1,845
Japanese Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	0		100,000
Revenue Received			250,000
U.S. Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	101,527		101,527
U.S. Pharmaceutical Company [Member] | Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	$ 260,766		$ 260,766

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 3,171	$ 4,739
Accrued payroll	978,255	679,277
Advances from related parties	56,500	0
Accrued purchases of property and equipment	0	174,801
Accrued research and development expenses	466,175	292,395
Accrued general and administrative expenses	421,432	315,294
Deferred rent	43,753	0
Total	$ 1,969,286	$ 1,466,506

Accrued Expenses And Other Cu25

Accrued Expenses And Other Current Liabilities - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)
Accrued Expenses and Other Current Liabilities [Line Items]
Proceeds from Convertible Debt	$ 65,000
Debt Instrument, Annual Principal Payment	$ 75,000
Debt Instrument, Maturity Date	Oct. 30, 2015
Non-Interest Bearing Advance [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Due To Officers Or Stockholders, Current	$ 401,575
Interest Bearing Advance [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Due To Officers Or Stockholders, Current	$ 280,075

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Outstanding, December 31, 2014				$ 5,738,239
Issuance				1,103,018
Indebtedness satisfied via settlement				(5,000)
Exchanges to equity				(5,020,478)
Conversions to equity				(188,333)
Recognition of debt discount				(186,635)
Accretion of interest expense				47,626	$ 0
Amortization of debt discount		$ 37,063	$ 137,167	177,947	$ 381,602
Outstanding, September 30, 2015		1,666,384		1,666,384
Debt Discount
Debt Instrument [Line Items]
Outstanding, December 31, 2014				(113,257)
Issuance				0
Indebtedness satisfied via settlement				0
Exchanges to equity				0
Conversions to equity				0
Recognition of debt discount	[1]			(186,635)
Accretion of interest expense	[1]			47,626
Amortization of debt discount				177,947
Outstanding, September 30, 2015		(74,319)		(74,319)
Bermuda Lender
Debt Instrument [Line Items]
Outstanding, December 31, 2014				4,410,937
Issuance				0
Indebtedness satisfied via settlement				0
Exchanges to equity				(4,410,937)
Conversions to equity				0
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, September 30, 2015		0		0
Convertible Notes
Debt Instrument [Line Items]
Outstanding, December 31, 2014				175,000
Issuance				625,000
Indebtedness satisfied via settlement				0
Exchanges to equity				(16,667)
Conversions to equity				(188,333)
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, September 30, 2015	[2]	595,000		595,000
Other Notes
Debt Instrument [Line Items]
Outstanding, December 31, 2014				1,265,559
Issuance				478,018
Indebtedness satisfied via settlement				(5,000)
Exchanges to equity				(592,874)
Conversions to equity				0
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, September 30, 2015		$ 1,145,703		$ 1,145,703
[1]	During the nine months ended September 30, 2015, notes in the aggregate amount of $538,018 bear no interest and were issued for cash consideration of $450,015. The $88,003 difference between the principal amount of the notes and the cash received was recorded as debt discount and is being amortized to interest expense over the term of the notes.
[2]	As of September 30, 2015, convertible notes with an aggregate principal balance of $595,000 were convertible into shares of common stock at the election of the Company. Of such aggregate principal balance, under certain circumstances, the holder has the right to convert $190,000 in principal into shares of common stock.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 29, 2015	May. 27, 2015	May. 11, 2015
Debt Instrument [Line Items]
Loss on extinguishment of note payables, net	$ 0		$ 0	$ 26,029	$ 49,094
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 0			$ 10,690	86,563
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10			$ 10
Amortization Of Debt Discount (Premium)	$ 37,063		137,167	$ 177,947	381,602
Proceeds from Convertible Debt				65,000
Class of Warrant or Right, Outstanding						5,000
Gains (Losses) On Extinguishment Of Debt	0		0	$ (26,029)	(49,094)
Class Of Warrant Or Rights Expiration Date		Dec. 31, 2015
Debt Instrument, Convertible, Terms of Conversion Feature				July 2015 and March 2016
Debt Instrument, Annual Principal Payment	75,000			$ 75,000
Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature				0
Other Notes Payable
Debt Instrument [Line Items]
Debt instrument, face amount	538,018			538,018
Amortization Of Debt Discount (Premium)				88,003
Proceeds from Convertible Debt				450,015
Scenario, Previously Reported [Member]
Debt Instrument [Line Items]
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value	15,249			15,249
In exchange of notes payable
Debt Instrument [Line Items]
Debt instrument, face amount	$ 430,000			430,000
Loss on extinguishment of note payables, net				$ 20,197
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,756			25,756
Debt Conversion, Original Debt, Amount				$ 592,874
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15			$ 15
Amortization Of Debt Discount (Premium)				$ 0
Gains (Losses) On Extinguishment Of Debt				$ (20,197)
Debt Conversion, Converted Instrument, Shares Issued				103,030
Accrued Interest Converted Into Stock	$ 25,296			$ 25,296
Warrants and Rights Outstanding	92,725			92,725
Convertible Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 595,000			595,000
Loss on extinguishment of note payables, net				$ 504
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,885			25,885
Debt instrument, new proceeds				$ 31
Debt Instrument Unamortized Discount	$ 82,042			82,042
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 45,179		$ 86,563
Debt Conversion, Original Debt, Amount				$ 188,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10			$ 10
Amortization Of Debt Discount (Premium)				$ 0
Proceeds from Convertible Debt				190,000
Gains (Losses) On Extinguishment Of Debt				$ (504)
Debt Instrument, Convertible, Terms of Conversion Feature				The convertible notes are convertible into shares of the Company's common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 55% to 65% of the fair value of the Company's common stock or (b) $2.00 or $3.00 per share depending on the note
Debt Conversion, Converted Instrument, Shares Issued				3,600
Debt Conversion Original Debt Shares Issued				41,359
Original Debt Accrued Interest Converted Into Stock	$ 13,468			$ 13,468
Conversion Debt Accrued Interest Converted Into Stock	827			827
Convertible Notes | Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount				16,667
Convertible Notes | Other Notes Payable One
Debt Instrument [Line Items]
Debt instrument, face amount	625,000			625,000
Debt Instrument Periodic Payment Interest				10,000
Proceeds from Convertible Debt				615,000
Convertible Notes | Other Notes Payable Two
Debt Instrument [Line Items]
Debt instrument, face amount	$ 478,018			478,018
Debt Instrument Periodic Payment Interest				78,003
Proceeds from Convertible Debt				$ 400,015
Convertible Notes | Minimum
Debt Instrument [Line Items]
Rate of interest	1.00%			1.00%
Debt Instrument, Convertible, Conversion Price	$ 4.44			$ 4.44
Convertible Notes | Maximum
Debt Instrument [Line Items]
Rate of interest	12.00%			12.00%
Debt Instrument, Convertible, Conversion Price	$ 5.16			$ 5.16
Bermuda Lender
Debt Instrument [Line Items]
Debt instrument, face amount							$ 4,410,937
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							186,682
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 15
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable				746,730
Debt Default, Short-term Debt, Amount								$ 316,297
Interest Payable							$ 69,436
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value							$ 672,056
Bermuda Lender | Warrants
Debt Instrument [Line Items]
Loss on extinguishment of note payables, net				$ (5,327)
Gains (Losses) On Extinguishment Of Debt				$ 5,327
Bermuda Lender | Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Outstanding	40,000			40,000
Bermuda Lender | Cayman
Debt Instrument [Line Items]
Aggregate principal amount								$ 410,938

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Aug. 13, 2015	Mar. 09, 2015	Feb. 09, 2015	Nov. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 29, 2015
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted							66,000
Common stock exercise price							$ 8.80
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10		$ 10
Loss Contingency, Allegations				The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
Operating Leases, Rent Expense, Net					$ 33,000	$ 3,000	$ 97,000	$ 17,000
Class of Warrant or Right, Outstanding									5,000
Legal Settlement Agreement [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues							4,230
Class of Warrant or Right, Outstanding					30,000		30,000
Proceeds from Issuance of Warrants							$ 152,000
Legal Settlement Agreement [Member] | Minimum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 7.60		$ 7.60
Legal Settlement Agreement [Member] | Maximum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 12		$ 12
Chief Executive Officer
Commitments and Contingencies Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Description		the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company's Compensation Committee, are satisfied
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 100,000
Division President
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted			25,000
Common stock exercise price			$ 9.20
Severance Costs			$ 150,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value			$ 200,400
Business Advisory Services
Commitments and Contingencies Disclosure [Line Items]
Fair Value Adjustment of Warrants	$ 74,923
Business Advisory Services | Extension 1
Commitments and Contingencies Disclosure [Line Items]
Additional Monthly Fee For Services Rendered	$ 15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12
Payments for Repurchase of Warrants	$ 10,000
Business Advisory Services | Extension 2
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10
Payments for Repurchase of Warrants	$ 10,000
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Severance Costs		125,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 300,000

Black-Scholes Option Pricing Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) - Warrants	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years	5 years	5 years
Expected volatility	120.00%	116.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.50%	1.64%	1.32%	0.39%
Expected term (years)				1 year 11 months 16 days
Expected volatility			120.00%	116.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.69%	1.76%	1.71%	2.20%
Expected term (years)				5 years
Expected volatility			122.00%	129.00%

Summary of Warrant Activity (De

Summary of Warrant Activity (Detail) - Warrants	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Number of Warrants
Beginning Balance | shares	412,422
Granted | shares	379,912
Exercised | shares	0
Forfeited | shares	0
Ending Balance | shares	792,334
Exercisable | shares	757,334
Weighted Average Exercise Price
Beginning Balance	$ 17.97
Granted	13.25
Exercised	0
Forfeited	0
Ending Balance	15.71
Exercisable	$ 15.05
Weighted Average Remaining Life In Years
Outstanding	3 years 8 months 12 days
Exercisable	3 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding | $	$ 0
Exercisable | $	$ 0

Summarized Information Related

Summarized Information Related to Stock Warrants (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	792,334
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	757,334
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	178,788
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	178,788
Exercise Price 1 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price 1 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	36,500
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	36,500
Exercise Price 2 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 14.99
Exercise Price 2 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10.01
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	458,388
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	458,388
Exercise Price 3 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price 3 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 15
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	83,658
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	83,658
Exercise Price 4 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 80
Exercise Price 4 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, Exercise Price Description	Variable	[1]
Warrants Outstanding, Number of Warrants	35,000
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years
Warrants Exercisable, Exercisable Number of Warrants	0
[1]	Warrants to purchase 35,000 shares of common stock have an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the nine months ended September 30, 2015.

Black-Scholes Option Pricing 32

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) - Stock Options	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.82%
Expected term (years)		5 years
Expected volatility	120.00%	116.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.39%		1.33%	1.50%
Expected term (years)	5 years		5 years	5 years
Expected volatility			120.00%	116.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.58%		1.64%	2.54%
Expected term (years)	10 years		10 years	10 years
Expected volatility			122.00%	121.00%

Information Related to Stock Op

Information Related to Stock Option Expense (Detail) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense				$ 74,923
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 235,197	$ 137,217	719,723	$ 647,485
Unrecognized expense		1,761,803		$ 1,761,803
Weighted Average Remaining Amortization Period (Years)				2 years 1 month 6 days
Consulting | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		60,383	35,662	$ 178,613	287,237
Unrecognized expense		415,863		$ 415,863
Weighted Average Remaining Amortization Period (Years)				2 years
Research and development | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		115,625	80,275	$ 348,777	233,989
Unrecognized expense	[1]	666,047		$ 666,047
Weighted Average Remaining Amortization Period (Years)				2 years 3 months 18 days
General and administrative | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		59,189	$ 21,280	$ 192,333	$ 126,259
Unrecognized expense		$ 679,893		$ 679,893
Weighted Average Remaining Amortization Period (Years)				2 years
[1]	Includes $252,937 of unrecognized expense that is subject to non-employee mark-to-market adjustments.

Summary of Stock Option Activit

Summary of Stock Option Activity (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015
Number of Options
Outstanding	779,200
Granted	66,000
Exercised	0
Forfeited	(35,000)
Outstanding	810,200
Exercisable	476,160
Weighted Average Exercise Price
Outstanding	$ 12.18
Granted	8.80
Exercised	0
Forfeited	6.34
Outstanding	12.16
Exercisable	$ 14.94
Weighted Average Remaining Life In Years
Outstanding	7 years 9 months 18 days
Exercisable	7 years 3 months 18 days
Intrinsic Value
Outstanding	$ 0
Exercisable	$ 0

Information Related to Stock 35

Information Related to Stock Options (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	810,200
Options Exercisable, Weighted Average Remaining Life In Years	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	476,160
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	353,750
Options Exercisable, Weighted Average Remaining Life In Years	8 years 6 months
Options Exercisable, Exercisable Number of Options	129,583
Exercise Price 1 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6.99
Exercise Price 1 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5.70
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	69,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years
Options Exercisable, Exercisable Number of Options	7,375
Exercise Price 2 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price 2 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 7
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	202,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	160,752
Exercise Price 3 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price 3 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	185,450
Options Exercisable, Weighted Average Remaining Life In Years	6 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	178,450
Exercise Price 4 | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30
Exercise Price 4 | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20

Information Related to Common S

Information Related to Common Stock Award Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense			$ 74,923
Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 42,500	$ 93,990	141,647	$ 334,388
Unrecognized expense	0		0
Consulting | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	42,500	88,200	132,800	322,700
Unrecognized expense	0		0
Research and development | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	0	$ 5,790	8,847	$ 11,688
Unrecognized expense	$ 0		$ 0

Stockholders' Deficiency - Addi

Stockholders' Deficiency - Additional Information (Detail) - USD ($)	Sep. 04, 2015	Apr. 06, 2015	May. 29, 2015	Jan. 23, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Aug. 13, 2015	Jul. 07, 2015	Jan. 02, 2015	Dec. 31, 2014	Dec. 19, 2014
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense							$ 74,923
Weighted average estimated fair value of stock options granted					$ 7.52	$ 5.40	$ 7.60	$ 4.80
Stock-based compensation, stock option granted							66,000
Stock-based compensation, stock options granted, exercise price							$ 8.80
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued							27,698
Grant date fair value							$ 141,647
Common stock, Authorized					30,000,000		30,000,000			30,000,000	200,000,000	30,000,000	100,000,000
Preferred stock, Authorized					5,000,000		5,000,000				5,000,000	5,000,000	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10		$ 10
Class of Warrant or Right, Outstanding			5,000
Class Of Warrant Or Rights Expiration Date			Dec. 31, 2017
Warrant Or Right Expense Or Revenue Recognized					$ 6,215		$ 16,215
Warrants to Purchase of Common Stock							24,500
Options to Purchase of Common Stock	505,250
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price					$ 12.16		$ 12.16					$ 12.18
Employee Stock Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number									157,900
Investor
Stockholders Equity Note Disclosure [Line Items]
Class Of Warrant Or Right Term							5 years
Exercise Price Dollor Greaterthan 30.00
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted							35,000
Share based compensation shares authorized under stock option plans exercise price					$ 30		$ 30
Director
Stockholders Equity Note Disclosure [Line Items]
Options to Purchase of Common Stock		15,000
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price		$ 8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 104,100
Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Share granted vested					7,500		7,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total					21,000
Professional Services
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services							943
Stock Issued During Period, Value, Issued for Services							$ 8,481
Director Employee Advisors And Consultant [Member]
Stockholders Equity Note Disclosure [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price	$ 7
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	201,750
Director Employee Advisors And Consultant One [Member]
Stockholders Equity Note Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	303,500
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share					$ 4.21	$ 3	$ 3.63	$ 3.40
Consultant Awards | First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested					3,750		3,750
Consultant Awards | Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested					625		625
Consultant Awards | Third Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested					625		625
Consultant Awards | Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted				5,000
Stock-based compensation, stock options granted, exercise price				$ 9.40
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense					$ 74,923	$ 1,500		$ 168,626
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense							$ 252,937
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value							$ 39,200
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)							227,550
Warrants to purchase common stock					91,589		91,589
Warrants aggregate grant date fair value					$ 322,732		$ 322,732
Minimum
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
Shares Issued, Price Per Share					$ 11.60		$ 11.60
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price					8		$ 8
Estimated Forfeitures Related To Option Grants Annual Rate							0.00%	0.00%
Maximum
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,250,000
Shares Issued, Price Per Share					18.80		$ 18.80
Maximum | Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price					8.75
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price					$ 15		$ 15
Estimated Forfeitures Related To Option Grants Annual Rate							5.00%	5.00%

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) - USD ($)	Nov. 09, 2015	Oct. 14, 2015	Sep. 04, 2015	Oct. 31, 2015	Oct. 21, 2015	Nov. 19, 2015	Sep. 30, 2015	Oct. 09, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues							$ 1,361,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 10
Options to Purchase of Common Stock			505,250
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price							$ 12.16		$ 12.18
Other Accrued Liabilities, Noncurrent							$ 39,420		$ 5,195
Notes Payable, Other Payables
Subsequent Event [Line Items]
Debt Instrument, Face Amount							$ 430,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 15
Debt Conversion, Converted Instrument, Shares Issued							103,030
Convertible Notes Payable
Subsequent Event [Line Items]
Debt Instrument, Face Amount							$ 595,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 10
Debt Conversion, Converted Instrument, Shares Issued							3,600
Subsequent Event
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues				159,375
Sale of Stock, Price Per Share				$ 5
Stock Issued During Period, Value, New Issues				$ 637,500
Received non-interest bearing advances from officer				75,000
Repayments Short Term Advances				$ 31,500
Warrant Issued To Purchase Common Stock				125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5
Subsequent Event | Private Common Stock and Warrant Offerings [Member]
Subsequent Event [Line Items]
Options to Purchase of Common Stock						159,375
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price						$ 6
Subsequent Event | Private Common Stock and Warrant Offerings One [Member]
Subsequent Event [Line Items]
Options to Purchase of Common Stock						125,000
Proceeds from Issuance of Warrants						$ 500,000
Subsequent Event | Exchange Agreement [Member] | Lender One [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		110,944
Debt Instrument, Face Amount		$ 380,000
Debt Instrument, Increase, Accrued Interest		$ 63,776
Warrant Issued To Purchase Common Stock		110,944
Warrants Exercisable Term		5 years
Guaranteed Interest Rate Of Classified Principal Amount		$ 25,000
Subsequent Event | Exchange Agreement [Member] | Lender Two [Member]
Subsequent Event [Line Items]
Warrants Exercisable Term					5 years
Subsequent Event | Exchange Agreement [Member] | Lender Three [Member]
Subsequent Event [Line Items]
Warrants Exercisable Term					5 years
Subsequent Event | Convertible Notes Payable
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Convertible, Conversion Price	$ 3
Debt Instrument Carrying Amount	$ 25,000
Debt Conversion, Converted Instrument, Shares Issued	8,742
Interest Receivable	$ 1,226
Subsequent Event | Two Month Notes Payable | Brown Fat Program [Member]
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage								10.00%
Debt Instrument, Face Amount								$ 150,000